0:00
Hello, my name is Dr. John Frew.
I'm a dermatologist and
dermatological
researcher based at
the Department of Dermatology at
Liverpool Hospital in
Sydney, Australia.
I will be speaking to
you today regarding
hidradenitis suppurativa or HS,
including our current
understanding
of the pathophysiology,
clinical features, and
treatment of the disease.
0:23
These are some of my disclosures
regarding work in HS,
involvement in clinical trials
and involvement in
consulting work
for various pharmaceutical
and industry bodies.
0:37
First of all, today,
I will be speaking to
the pathophysiology of
hidradenitis suppurativa.
This is a complex and
ever-evolving area
of research and we understand
a great deal more about
the mechanisms involved in
HS than we did even a
few short years ago.
0:55
Clinically, hidradenitis
suppurativa,
also known as HS
or acne inversa,
is a chronic inflammatory
disease that manifests in
inflamed erythematous
nodules, painful,
malodorous draining tunnels,
as well as fluctuant
purulent abscesses
with a predilection
to flexural areas of skin.
It has an extremely
high disease burden
and impact on quality of life.
It affects individuals of
all backgrounds and ages,
but most commonly occurs in
late adolescence or in
individuals in their twenties.
Although there certainly is
some evidence to suggest that
middle aged individuals are
also prone to
developing the disease.
It is not an uncommon disease
and has an estimated prevalence
around 1 percent of
the general population in
all areas of the globe.
